Search

Your search keyword '"Wahner Hendrickson, Andrea E."' showing total 186 results
Start Over Author "Wahner Hendrickson, Andrea E."
186 results on '"Wahner Hendrickson, Andrea E."'

2. Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study

Author

duPont, Nefertiti C, Enserro, Danielle, Brady, Mark F, Moxley, Katherine, Walker, Joan L, Cosgrove, Casey, Bixel, Kristin, Tewari, Krishnansu S, Thaker, Premal, Wahner Hendrickson, Andrea E, Rubin, Stephen, Fujiwara, Keiichi, Casey, A Catherine, Soper, John, Burger, Robert A, and Monk, Bradley J

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Ovarian Cancer, Clinical Trials and Supportive Activities, Clinical Research, Rare Diseases, Prevention, Patient Safety, Adenocarcinoma, Black or African American, Age Factors, Aged, Aged, 80 and over, Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Asian, Bevacizumab, Carboplatin, Carcinoma, Endometrioid, Carcinoma, Ovarian Epithelial, Chemotherapy, Adjuvant, Ethnicity, Fallopian Tube Neoplasms, Female, Hispanic or Latino, Humans, Middle Aged, Neoplasm Staging, Neoplasms, Cystic, Mucinous, and Serous, Ovarian Neoplasms, Paclitaxel, Peritoneal Neoplasms, Prognosis, Proportional Hazards Models, Survival Rate, White People, Minority populations, Asian women, African American women, Elderly, Ovarian cancer, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

BackgroundAge and ethnicity are among several factors that influence overall survival (OS) in ovarian cancer. The study objective was to determine whether ethnicity and age were of prognostic significance in women enrolled in a clinical trial evaluating the addition of bevacizumab to front-line therapy.MethodsWomen with advanced stage ovarian, primary peritoneal, or fallopian tube cancer were enrolled in a phase III clinical trial. All women had surgical staging and received adjuvant chemotherapy with one of three regimens. Cox proportional hazards models were used to evaluate the relationship between OS with age and race/ethnicity among the study participants.ResultsOne-thousand-eight-hundred-seventy-three women were enrolled in the study. There were 280 minority women and 328 women over the age of 70. Women age 70 and older had a 34% increase risk for death when compared to women under 60 (HR = 1.34; 95% CI 1.16-1.54). Non-Hispanic Black women had a 54% decreased risk of death with the addition of maintenance bevacizumab (HR = 0.46, 95% CI:0.26-0.83). Women of Asian descent had more hematologic grade 3 or greater adverse events and a 27% decrease risk of death when compared to non-Hispanic Whites (HR = 0.73; 95% CI: 0.59-0.90).ConclusionsNon-Hispanic Black women showed a decreased risk of death with the addition of bevacizumab and patients of Asian ancestry had a lower death rate than all other minority groups, but despite these clinically meaningful improvements there was no statistically significant difference in OS among the groups.

Published
2022

3. Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial

Author

Liu, Joyce F., Gaillard, Stéphanie, Wahner Hendrickson, Andrea E., Yeku, Oladapo, Diver, Elisabeth, Gunderson Jackson, Camille, Arend, Rebecca, Ratner, Elena, Samnotra, Vivek, Gupta, Divya, Chung, Jon, Zhang, Hailei, Compton, Natalie, Baines, Amanda, Bacqué, Emeline, Liu, Xiaohong, Felicetti, Brunella, and Konecny, Gottfried E.

Published
2024
Full Text
View/download PDF

4. PARP inhibitor maintenance for primary ovarian cancer – A missed opportunity for precision medicine

Author

Wethington, Stephanie L, Wahner-Hendrickson, Andrea E, Swisher, Elizabeth M, Kaufmann, Scott H, Karlan, Beth Y, Fader, Amanda Nickles, and Dowdy, Sean C

Subjects
Reproductive Medicine, Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, BRCA1 Protein, BRCA2 Protein, DNA Repair-Deficiency Disorders, Female, Humans, Mutation, Ovarian Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Precision Medicine, Randomized Controlled Trials as Topic, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Published
2021

5. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).

Author

Swisher, Elizabeth M, Kwan, Tanya T, Oza, Amit M, Tinker, Anna V, Ray-Coquard, Isabelle, Oaknin, Ana, Coleman, Robert L, Aghajanian, Carol, Konecny, Gottfried E, O'Malley, David M, Leary, Alexandra, Provencher, Diane, Welch, Stephen, Chen, Lee-May, Wahner Hendrickson, Andrea E, Ma, Ling, Ghatage, Prafull, Kristeleit, Rebecca S, Dorigo, Oliver, Musafer, Ashan, Kaufmann, Scott H, Elvin, Julia A, Lin, Douglas I, Chambers, Setsuko K, Dominy, Erin, Vo, Lan-Thanh, Goble, Sandra, Maloney, Lara, Giordano, Heidi, Harding, Thomas, Dobrovic, Alexander, Scott, Clare L, Lin, Kevin K, and McNeish, Iain A

Subjects
Humans, Ovarian Neoplasms, Neoplasm Recurrence, Local, Platinum, Indoles, DNA-Binding Proteins, BRCA1 Protein, BRCA2 Protein, Antineoplastic Agents, DNA Methylation, Adult, Aged, Aged, 80 and over, Middle Aged, Female, Promoter Regions, Genetic, Poly(ADP-ribose) Polymerase Inhibitors, Carcinoma, Ovarian Epithelial
Abstract

ARIEL2 (NCT01891344) is a single-arm, open-label phase 2 study of the PARP inhibitor (PARPi) rucaparib in relapsed high-grade ovarian carcinoma. In this post hoc exploratory biomarker analysis of pre- and post-platinum ARIEL2 samples, RAD51C and RAD51D mutations and high-level BRCA1 promoter methylation predict response to rucaparib, similar to BRCA1/BRCA2 mutations. BRCA1 methylation loss may be a major cross-resistance mechanism to platinum and PARPi. Genomic scars associated with homologous recombination deficiency are irreversible, persisting even as platinum resistance develops, and therefore are predictive of rucaparib response only in platinum-sensitive disease. The RAS, AKT, and cell cycle pathways may be additional modulators of PARPi sensitivity.

Published
2021

6. Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses

Author

Konstantinopoulos, Panagiotis A., Cheng, Su-Chun, Lee, Elizabeth K., da Costa, Alexandre André B.A., Gulhan, Doga, Wahner Hendrickson, Andrea E., Kochupurakkal, Bose, Kolin, David L., Kohn, Elise C., Liu, Joyce F., Penson, Richard T., Stover, Elizabeth H., Curtis, Jennifer, Sawyer, Hannah, Polak, Madeline, Chowdhury, Dipanjan, DʼAndrea, Alan D., Färkkilä, Anniina, Shapiro, Geoffrey I., and Matulonis, Ursula A.

Published
2024
Full Text
View/download PDF

8. A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283

Author

O'Cearbhaill, Roisin E., Miller, Austin, Soslow, Robert A., Lankes, Heather A., DeLair, Deborah, Segura, Sheila, Chavan, Shweta, Zamarin, Dmitriy, DeBernardo, Robert, Moore, Kathleen, Moroney, John, Shahin, Mark, Thaker, Premal H., Wahner-Hendrickson, Andrea E., and Aghajanian, Carol

Published
2023
Full Text
View/download PDF

9. Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study

Author

Praiss, Aaron M., Miller, Austin, Smith, Judith, Lichtman, Stuart M., Bookman, Michael, Aghajanian, Carol, Sabbatini, Paul, Backes, Floor, Cohn, David E., Argenta, Peter, Friedlander, Michael, Goodheart, Michael J., Mutch, David G., Gershenson, David M., Tewari, Krishnansu S., Wenham, Robert M., Wahner Hendrickson, Andrea E., Lee, Roger B., Gray, Heidi, Secord, Angeles Alvarez, Van Le, Linda, and O'Cearbhaill, Roisin E.

Published
2023
Full Text
View/download PDF

10. The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study

Author

Sia, Tiffany Y., Tew, William P., Purdy, Christopher, Chi, Dennis S., Menzin, Andrew W., Lovecchio, John L., Bookman, Michael A., Cohn, David E., Teoh, Deanna G., Friedlander, Michael, Bender, David, Mutch, David G., Gershenson, David M., Tewari, Krishnansu S., Wenham, Robert M., Wahner Hendrickson, Andrea E., Lee, Roger B., Gray, Heidi J., Secord, Angeles Alvarez, Van Le, Linda, and Lichtman, Stuart M.

Published
2023
Full Text
View/download PDF

11. A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer

Author

Manzo, Julia, Puhalla, Shannon, Pahuja, Shalu, Ding, Fei, Lin, Yan, Appleman, Leonard, Tawbi, Hussein, Stoller, Ronald, Lee, James J., Diergaarde, Brenda, Kiesel, Brian F., Yu, Jing, Tan, Antoinette R., Belani, Chandra P., Chew, Helen, Garcia, Agustin A., Morgan, Robert J., Wahner Hendrickson, Andrea E., Visscher, Daniel W., Hurley, Rachel M., Kaufmann, Scott H., Swisher, Elizabeth M., Oesterreich, Steffi, Katz, Tiffany, Ji, Jiuping, Zhang, Yiping, Parchment, Ralph E., Chen, Alice, Duan, Wenrui, Giranda, Vincent, Shepherd, Stacie P., Ivy, S. Percy, Chu, Edward, and Beumer, Jan H.

Published
2022
Full Text
View/download PDF

12. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours

Author

Konstantinopoulos, Panagiotis A., Cheng, Su-Chun, Supko, Jeffrey G., Polak, Madeline, Wahner-Hendrickson, Andrea E., Ivy, S. Percy, Bowes, Brittany, Sawyer, Hannah, Basada, Patrice, Hayes, Martin, Curtis, Jennifer, Horowitz, Neil, Wright, Alexi A., Campos, Susana M., Ivanova, Elena V., Paweletz, Cloud P., Palakurthi, Sangeetha, Liu, Joyce F., D’Andrea, Alan D., Gokhale, Prafulla C., Chowdhury, Dipanjan, Matulonis, Ursula A., and Shapiro, Geoffrey I.

Published
2022
Full Text
View/download PDF

13. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

Author

Lheureux, Stephanie, Cristea, Mihaela C, Bruce, Jeffrey P, Garg, Swati, Cabanero, Michael, Mantia-Smaldone, Gina, Olawaiye, Alexander B, Ellard, Susan L, Weberpals, Johanne I, Wahner Hendrickson, Andrea E, Fleming, Gini F, Welch, Stephen, Dhani, Neesha C, Stockley, Tracy, Rath, Prisni, Karakasis, Katherine, Jones, Gemma N, Jenkins, Suzanne, Rodriguez-Canales, Jaime, Tracy, Michael, Tan, Qian, Bowering, Valerie, Udagani, Smitha, Wang, Lisa, Kunos, Charles A, Chen, Eric, Pugh, Trevor J, and Oza, Amit M

Published
2021
Full Text
View/download PDF

14. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

Author

Konstantinopoulos, Panagiotis A, Cheng, Su-Chun, Wahner Hendrickson, Andrea E, Penson, Richard T, Schumer, Susan T, Doyle, L Austin, Lee, Elizabeth K, Kohn, Elise C, Duska, Linda R, Crispens, Marta A, Olawaiye, Alexander B, Winer, Ira S, Barroilhet, Lisa M, Fu, Siqing, McHale, Michael T, Schilder, Russell J, Färkkilä, Anniina, Chowdhury, Dipanjan, Curtis, Jennifer, Quinn, Roxanne S, Bowes, Brittany, D'Andrea, Alan D, Shapiro, Geoffrey I, and Matulonis, Ursula A

Published
2020
Full Text
View/download PDF

15. A Phase I trial of Nab-Paclitaxel/Bevacizumab (AB160) Nano-Immunoconjugate Therapy for Gynecologic Malignancies

Author

Kalogera, Eleftheria, primary, Nevala, Wendy K., additional, Finnes, Heidi D., additional, Suman, Vera J., additional, Schimke, Jill M., additional, Strand, Carrie A., additional, Kottschade, Lisa A., additional, Kudgus, Rachel A., additional, Buhrow, Sarah A., additional, Becher, Laura R., additional, Geng, Liyi, additional, Glaser, Gretchen E., additional, Grudem, Megan E., additional, Jatoi, Aminah, additional, Klampe, Carolyn M., additional, Kumar, Amanika, additional, Langstraat, Carrie L., additional, McWilliams, Robert R., additional, Wahner Hendrickson, Andrea E., additional, Weroha, S. John, additional, Yan, Yiyi, additional, Reid, Joel M., additional, Markovic, Svetomir N., additional, and Block, Matthew S., additional

Published
2024
Full Text
View/download PDF

18. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

Author

Moore, Kathleen N, Secord, Angeles Alvarez, Geller, Melissa A, Miller, David Scott, Cloven, Noelle, Fleming, Gini F, Wahner Hendrickson, Andrea E, Azodi, Masoud, DiSilvestro, Paul, Oza, Amit M, Cristea, Mihaela, Berek, Jonathan S, Chan, John K, Rimel, Bobbie J, Matei, Daniela E, Li, Yong, Sun, Kaiming, Luptakova, Katarina, Matulonis, Ursula A, and Monk, Bradley J

Published
2019
Full Text
View/download PDF

19. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer

Author

Hurley, Rachel M., Wahner Hendrickson, Andrea E., Visscher, Daniel W., Ansell, Peter, Harrell, Maria I., Wagner, Jill M., Negron, Vivian, Goergen, Krista M., Maurer, Matthew J., Oberg, Ann L., Meng, X. Wei, Flatten, Karen S., De Jonge, Maja J.A., Van Herpen, Carla D., Gietema, Jourik A., Koornstra, Rutger H.T., Jager, Agnes, den Hollander, Martha W., Dudley, Matthew, Shepherd, Stacie P., Swisher, Elizabeth M., and Kaufmann, Scott H.

Published
2019
Full Text
View/download PDF

21. Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients

Author

Block, Matthew S., Dietz, Allan B., Gustafson, Michael P., Kalli, Kimberly R., Erskine, Courtney L., Youssef, Bahaaeldin, Vijay, Geraldine V., Allred, Jacob B., Pavelko, Kevin D., Strausbauch, Michael A., Lin, Yi, Grudem, Megan E., Jatoi, Aminah, Klampe, Carolyn M., Wahner-Hendrickson, Andrea E., Weroha, S. John, Glaser, Gretchen E., Kumar, Amanika, Langstraat, Carrie L., Solseth, Mary L., Deeds, Michael C., Knutson, Keith L., and Cannon, Martin J.

Published
2020
Full Text
View/download PDF

22. Renal calyceal rupture with extensive urinoma formation as a complication of cervical cancer.

Author

Sardar, Sehrish, Hickman, Ashley, and Wahner Hendrickson, Andrea E.

Abstract

Renal calyceal rupture (RCR) is a rare phenomenon most commonly caused by increased renal pelvic pressure from ureteral obstruction. This can occur in the setting of acute obstruction such as with kidney stones and is not commonly seen as a consequence of malignancy due to the chronic nature of obstruction. In this case, we describe a patient with newly diagnosed cervical cancer presenting with thigh pain who was found to have a urinoma from RCR caused by malignant obstruction. We discuss the workup of a pelvic mass presenting as flank pain, as well as the role of history and physical exam when reviewing imaging. We also review the management of RCR in the setting of malignant obstruction. Lastly we highlight the alterations to cervical cancer treatment due to the presence of the infected urinoma. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Supplementary Methods and oligonucleotide sequences from BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents

Author

Kanakkanthara, Arun, primary, Kurmi, Kiran, primary, Ekstrom, Thomas L., primary, Hou, Xiaonan, primary, Purfeerst, Emma R., primary, Heinzen, Ethan P., primary, Correia, Cristina, primary, Huntoon, Catherine J., primary, O'Brien, Daniel, primary, Wahner Hendrickson, Andrea E., primary, Dowdy, Sean C., primary, Li, Hu, primary, Oberg, Ann L., primary, Hitosugi, Taro, primary, Kaufmann, Scott H., primary, Weroha, S. John, primary, and Karnitz, Larry M., primary

Published
2023
Full Text
View/download PDF

24. Data from BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents

Author

Kanakkanthara, Arun, primary, Kurmi, Kiran, primary, Ekstrom, Thomas L., primary, Hou, Xiaonan, primary, Purfeerst, Emma R., primary, Heinzen, Ethan P., primary, Correia, Cristina, primary, Huntoon, Catherine J., primary, O'Brien, Daniel, primary, Wahner Hendrickson, Andrea E., primary, Dowdy, Sean C., primary, Li, Hu, primary, Oberg, Ann L., primary, Hitosugi, Taro, primary, Kaufmann, Scott H., primary, Weroha, S. John, primary, and Karnitz, Larry M., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figures S1-6. from BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents

Author

Kanakkanthara, Arun, primary, Kurmi, Kiran, primary, Ekstrom, Thomas L., primary, Hou, Xiaonan, primary, Purfeerst, Emma R., primary, Heinzen, Ethan P., primary, Correia, Cristina, primary, Huntoon, Catherine J., primary, O'Brien, Daniel, primary, Wahner Hendrickson, Andrea E., primary, Dowdy, Sean C., primary, Li, Hu, primary, Oberg, Ann L., primary, Hitosugi, Taro, primary, Kaufmann, Scott H., primary, Weroha, S. John, primary, and Karnitz, Larry M., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Data from A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

Author

Wahner Hendrickson, Andrea E., primary, Menefee, Michael E., primary, Hartmann, Lynn C., primary, Long, Harry J., primary, Northfelt, Donald W., primary, Reid, Joel M., primary, Boakye-Agyeman, Felix, primary, Kayode, Olumide, primary, Flatten, Karen S., primary, Harrell, Maria I., primary, Swisher, Elizabeth M., primary, Poirier, Guy G., primary, Satele, Daniel, primary, Allred, Jake, primary, Lensing, Janet L., primary, Chen, Alice, primary, Ji, Jiuping, primary, Zang, Yiping, primary, Erlichman, Charles, primary, Haluska, Paul, primary, and Kaufmann, Scott H., primary

Published
2023
Full Text
View/download PDF

29. Data from Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 In vitro

Author

Wahner Hendrickson, Andrea E., primary, Haluska, Paul, primary, Schneider, Paula A., primary, Loegering, David A., primary, Peterson, Kevin L., primary, Attar, Ricardo, primary, Smith, B. Douglas, primary, Erlichman, Charles, primary, Gottardis, Marco, primary, Karp, Judith E., primary, Carboni, Joan M., primary, and Kaufmann, Scott H., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Table 1 from Expression of Insulin Receptor Isoform A and Insulin-like Growth Factor-1 Receptor in Human Acute Myelogenous Leukemia: Effect of the Dual-Receptor Inhibitor BMS-536924 In vitro

Author

Wahner Hendrickson, Andrea E., primary, Haluska, Paul, primary, Schneider, Paula A., primary, Loegering, David A., primary, Peterson, Kevin L., primary, Attar, Ricardo, primary, Smith, B. Douglas, primary, Erlichman, Charles, primary, Gottardis, Marco, primary, Karp, Judith E., primary, Carboni, Joan M., primary, and Kaufmann, Scott H., primary

Published
2023
Full Text
View/download PDF

38. 2022-RA-464-ESGO A phase i dose escalation and expansion cohort trial of carboplatin and gemcitabine with the ATR inhibitor berzosertib in first or second recurrence platinum sensitive epithelial ovarian, peritoneal, and fallopian tube cancer

Author

Wahner Hendrickson, Andrea E, primary, Foster, Nathan, additional, Corr, Bradley R, additional, Duska, Linda, additional, Markham, Merry J, additional, Butler, Kristina, additional, Girda, Eugenia, additional, Miller, Rachel Ware, additional, Arneson, Katherine, additional, Gano, Katherine, additional, Johnson, Janelle, additional, Shapiro, Geoffrey, additional, Rubinstein, Larry, additional, Percy Ivy, S, additional, Kohn, Elise, additional, Adjei, Alex, additional, and Kaufmann, Scott, additional

Published
2022
Full Text
View/download PDF

41. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours

Author

Konstantinopoulos, Panagiotis A., primary, Cheng, Su-Chun, additional, Supko, Jeffrey G., additional, Polak, Madeline, additional, Wahner-Hendrickson, Andrea E., additional, Ivy, S. Percy, additional, Bowes, Brittany, additional, Sawyer, Hannah, additional, Basada, Patrice, additional, Hayes, Martin, additional, Curtis, Jennifer, additional, Horowitz, Neil, additional, Wright, Alexi A., additional, Campos, Susana M., additional, Ivanova, Elena V., additional, Paweletz, Cloud P., additional, Palakurthi, Sangeetha, additional, Liu, Joyce F., additional, D’Andrea, Alan D., additional, Gokhale, Prafulla C., additional, Chowdhury, Dipanjan, additional, Matulonis, Ursula A., additional, and Shapiro, Geoffrey I., additional

Published
2021
Full Text
View/download PDF

42. CHFR and Paclitaxel Sensitivity of Ovarian Cancer

Author

Wahner Hendrickson, Andrea E., primary, Visscher, Daniel W., additional, Hou, Xiaonan, additional, Goergen, Krista M., additional, Atkinson, Hunter J., additional, Beito, Thomas G., additional, Negron, Vivian, additional, Lingle, Wilma L., additional, Bruzek, Amy K., additional, Hurley, Rachel M., additional, Wagner, Jill M., additional, Flatten, Karen S., additional, Peterson, Kevin L, additional, Schneider, Paula A, additional, Larson, Melissa C., additional, Maurer, Matthew J., additional, Kalli, Kimberly R., additional, Oberg, Ann L., additional, Weroha, S. John, additional, and Kaufmann, Scott H., additional

Published
2021
Full Text
View/download PDF

44. Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance

Author

Hurley, Rachel M, primary, McGehee, Cordelia D, additional, Nesic, Ksenija, additional, Correia, Cristina, additional, Weiskittel, Taylor M, additional, Kelly, Rebecca L, additional, Venkatachalam, Annapoorna, additional, Hou, Xiaonan, additional, Pathoulas, Nicholas M, additional, Meng, X Wei, additional, Kondrashova, Olga, additional, Radke, Marc R, additional, Schneider, Paula A, additional, Flatten, Karen S, additional, Peterson, Kevin L, additional, Becker, Marc A, additional, Wong, Ee Ming, additional, Southey, Melissa S, additional, Dobrovic, Alexander, additional, Lin, Kevin K, additional, Harding, Thomas C, additional, McNeish, Iain, additional, Ross, Christian A, additional, Wagner, Jill M, additional, Wakefield, Matthew J, additional, Scott, Clare L, additional, Haluska, Paul, additional, Wahner Hendrickson, Andrea E, additional, Karnitz, Larry M, additional, Swisher, Elizabeth M, additional, Li, Hu, additional, Weroha, S John, additional, and Kaufmann, Scott H, additional

Published
2021
Full Text
View/download PDF

46. Characterization of aRAD51C-Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development

Author

Hurley, Rachel M., primary, McGehee, Cordelia D., additional, Nesic, Ksenija, additional, Correia, Cristina, additional, Weiskittel, Taylor M., additional, Kelly, Rebecca L., additional, Venkatachalam, Annapoorna, additional, Hou, Xiaonan, additional, Pathoulas, Nicholas M., additional, Meng, X. Wei, additional, Kondrashova, Olga, additional, Radke, Marc R., additional, Schneider, Paula A., additional, Flatten, Karen S., additional, Peterson, Kevin L., additional, Dobrovic, Alexander, additional, Lin, Kevin K., additional, Harding, Thomas C, additional, McNeish, Iain A., additional, Ross, Christian A., additional, Wagner, Jill M., additional, Wakefield, Matthew J., additional, Scott, Clare L., additional, Haluska, Paul, additional, Wahner Hendrickson, Andrea E., additional, Karnitz, Larry M., additional, Swisher, Elizabeth M., additional, Li, Hu, additional, Weroha, S. John, additional, and Kaufmann, Scott H., additional

Published
2020
Full Text
View/download PDF

47. BRCA1 Deficiency Upregulates NNMT, Which Reprograms Metabolism and Sensitizes Ovarian Cancer Cells to Mitochondrial Metabolic Targeting Agents

Author

Kanakkanthara, Arun, primary, Kurmi, Kiran, additional, Ekstrom, Thomas L., additional, Hou, Xiaonan, additional, Purfeerst, Emma R., additional, Heinzen, Ethan P., additional, Correia, Cristina, additional, Huntoon, Catherine J., additional, O'Brien, Daniel, additional, Wahner Hendrickson, Andrea E., additional, Dowdy, Sean C., additional, Li, Hu, additional, Oberg, Ann L., additional, Hitosugi, Taro, additional, Kaufmann, Scott H., additional, Weroha, S. John, additional, and Karnitz, Larry M., additional

Published
2019
Full Text
View/download PDF

48. Open-label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

Author

Vinayak, Shaveta, primary, Tolaney, Sara M., additional, Schwartzberg, Lee, additional, Mita, Monica, additional, McCann, Georgia, additional, Tan, Antoinette R., additional, Wahner-Hendrickson, Andrea E., additional, Forero, Andres, additional, Anders, Carey, additional, Wulf, Gerburg M., additional, Dillon, Patrick, additional, Lynce, Filipa, additional, Zarwan, Corrine, additional, Erban, John K., additional, Zhou, Yinghui, additional, Buerstatte, Nathan, additional, Graham, Julie R., additional, Arora, Sujata, additional, Dezube, Bruce J., additional, and Telli, Melinda L., additional

Published
2019
Full Text
View/download PDF

50. A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors

Author

Wahner Hendrickson, Andrea E., primary, Menefee, Michael E., additional, Hartmann, Lynn C., additional, Long, Harry J., additional, Northfelt, Donald W., additional, Reid, Joel M., additional, Boakye-Agyeman, Felix, additional, Kayode, Olumide, additional, Flatten, Karen S., additional, Harrell, Maria I., additional, Swisher, Elizabeth M., additional, Poirier, Guy G., additional, Satele, Daniel, additional, Allred, Jake, additional, Lensing, Janet L., additional, Chen, Alice, additional, Ji, Jiuping, additional, Zang, Yiping, additional, Erlichman, Charles, additional, Haluska, Paul, additional, and Kaufmann, Scott H., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results